Tanner C M, Goetz C G, Glantz R H, Glatt S L, Klawans H L
Neurology. 1982 Oct;32(10):1175-9. doi: 10.1212/wnl.32.10.1175.
We studied the effects of pergolide mesylate in an open trial of 23 patients with idiopathic Parkinson disease (PD). All had suffered from loss of efficacy or dose-limiting side effects on current antiparkinsonian regimens. On pergolide therapy, improvement, which was maintained for 6 months, was noted in some parkinsonian features in all 23 patients. All patients suffering from on-off phenomenon were helped by pergolide. Significant side effects were not encountered. Pergolide is useful in the treatment of PD.
